List view / Grid view

Dr Mark Rutstein

 

article

Antibody-drug conjugates: paving the future of oncology clinical development

Dr Mark Rutstein, Senior Vice President, Head of Oncology Clinical…

26 October 2023 | By ,

Dr Mark Rutstein, Senior Vice President, Head of Oncology Clinical Development at Daiichi Sankyo, highlights key data about the company’s antibody-drug conjugate (ADC) being investigated for breast and lung cancer, and shares insight into why ADCs could replace current standards of care in oncology.